Mission Statement, Vision, & Core Values of Neuronetics, Inc. (STIM)

Neuronetics, Inc. (STIM) defines its purpose with a clear mission: renewing lives by transforming neurohealth, but how does that noble vision align with the financial reality of a projected $147 million to $150 million in full-year 2025 revenue? You're looking at a medical technology company that has delivered over 8.2 million transcranial magnetic stimulation (TMS) treatment sessions, yet their Q3 2025 earnings showed a net loss of $9.4 million despite total revenue hitting $37.3 million.

The strategic acquisition of Greenbrook TMS Inc. defintely drove revenue-Q3 clinic revenue was $21.8 million-but it also compressed the gross margin down to 45.9% from 75.6% a year prior. Are the company's core values of integrity and excellence strong enough to navigate the margin pressure and CEO transition announced in November 2025, and fundamentally, what does this mean for the long-term value of their NeuroStar® Advanced Therapy system?

Neuronetics, Inc. (STIM) Overview

You need a clear picture of Neuronetics, Inc.'s current standing-where they came from, what they sell, and what their latest numbers actually mean for the business. The direct takeaway is this: Neuronetics is a commercial-stage medical technology company that has cemented its position as the market leader in non-invasive brain stimulation therapy, and its 2025 revenue is on track to hit a range of $147 million to $150 million, largely due to a strategic acquisition.

Neuronetics, Inc. was founded in 2003 in Malvern, Pennsylvania, with a focus on developing non-invasive treatments for psychiatric disorders that often resist traditional medication. Their flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation (TMS) to target brain areas associated with mood regulation, primarily for Major Depressive Disorder (MDD). They were the first to receive U.S. Food and Drug Administration (FDA) clearance for a TMS device to treat medication-refractory MDD.

The company operates a two-pronged sales model: selling the NeuroStar system and generating recurring revenue from treatment sessions and their clinic network. The acquisition of Greenbrook TMS Inc. in late 2024 radically changed their revenue profile, adding a significant clinic-based service component. For the full fiscal year 2025, the company projects total worldwide revenue to be between $147 million and $150 million. This combination of technology and service delivery is key to understanding their current valuation. If you want to dig deeper into their foundational structure, you can find a comprehensive breakdown here: Neuronetics, Inc. (STIM): History, Ownership, Mission, How It Works & Makes Money.

Here's the quick math on their recent sales composition:

• Total Q3 2025 Revenue: $37.3 million
• U.S. Greenbrook Clinic Revenue: $21.8 million in Q3 2025
• U.S. NeuroStar System Revenue: $3.5 million in Q3 2025

Financial Performance: Q3 2025 Revenue Drivers

The third quarter of 2025 was defintely a pivotal period, showing the full impact of the Greenbrook integration on Neuronetics' financial statements. Total revenue for Q3 2025 hit $37.3 million, which marks a massive 101% increase on an unadjusted basis compared to Q3 2024. But, to be fair, that growth is mostly due to the clinic business acquisition, so the adjusted pro forma increase of 11% is a more realistic measure of organic momentum.

The main product sales story has shifted. The new revenue leader is the U.S. Greenbrook clinic business, which generated $21.8 million in Q3 2025. This segment showed a strong 25% growth on an adjusted pro forma basis versus the prior year quarter, demonstrating successful integration and high patient volume. The U.S. NeuroStar Advanced Therapy System revenue, which is the actual device sales, was $3.5 million in the quarter, with 40 systems shipped. This shift in revenue mix, where the lower-margin clinic business now dominates, is why the gross margin dropped to 45.9% from 75.6% in Q3 2024.

Still, the balance sheet looks stronger. The company ended Q3 2025 with $34.5 million in total cash, a significant improvement from $19.5 million at the end of 2024, indicating better cash management. This cash position is a solid foundation for their projected Q4 2025 revenue of between $40 million and $43 million. Strong clinic performance is driving the business.

Neuronetics: The Leader in Neurohealth Solutions

Neuronetics, Inc. is not just a player in the neurohealth space; it is the leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the industry. Their flagship product, the NeuroStar Advanced Therapy System, is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. This clinical proof is the real barrier to entry for competitors.

The company has achieved significant milestones that underscore its market dominance and impact on patient care. As of late 2025, the NeuroStar system has treated over 229,429 global patients, delivering more than 8.2 million treatment sessions. Plus, they are actively expanding access, securing expanded New York State Medicaid coverage for NeuroStar, which potentially reaches over 5 million members statewide. This combination of clinical evidence, patient volume, and expanding reimbursement makes them a clear leader. You need to understand how this market position drives their financial success, so let's find out more below.

Neuronetics, Inc. (STIM) Mission Statement

You're looking for the anchor points of a medical technology company like Neuronetics, Inc., and honestly, it all starts with the mission. For Neuronetics, the direct takeaway is that they're not just selling a device; they are focused on renewing lives by transforming neurohealth. That's the core mandate. This mission is critical because it guides every capital expenditure decision-like the Greenbrook TMS Inc. acquisition-and every R&D dollar spent on their flagship NeuroStar Advanced Therapy system.

This long-term goal isn't abstract, either. It maps directly to their ultimate vision of achieving neurohealth for people everywhere. When you look at their 2025 financial guidance, which projects total worldwide revenue between $147 million and $150 million, you see the commercial engine backing this mission. This isn't just about growth; it's the scale needed to make a real impact on mental health care, which is defintely a huge need.

The mission breaks down into three actionable pillars that drive their strategy and, ultimately, investor value. You can dive deeper into the company's background and strategy here: Neuronetics, Inc. (STIM): History, Ownership, Mission, How It Works & Makes Money.

Pillar 1: Transforming Neurohealth through Innovation

The first core component is innovation, which means continuously seeking and developing new technologies and treatments. Neuronetics' primary product, the NeuroStar Advanced Therapy system, uses transcranial magnetic stimulation (TMS)-a non-drug, non-invasive treatment-to stimulate brain areas tied to mood regulation.

This focus on innovation is what drives their clinical pipeline and market expansion. For instance, the company is committed to advancing the body of scientific research, which is why they present data derived from the TrakStar® data set-the largest real-world outcomes database in TMS-at events like the 2025 Clinical TMS Society Annual Meeting. They shipped 40 NeuroStar systems in the third quarter of 2025 alone, generating $3.5 million in U.S. system revenue, which shows a steady investment in expanding the technology's footprint.

Here's the quick math on their reach:

• 7.6 million+ treatments delivered as of October 2025.
• 202,000+ global patients treated as of May 2025.

That kind of scale is only possible with a product that stays on the cutting edge of non-invasive treatment.

Pillar 2: Delivering Exceptional Patient Outcomes and Quality

The second pillar is a commitment to excellence, which translates directly into delivering high-quality products and services that produce extraordinary results. This isn't just a marketing slogan; it's backed by the largest clinical data set of any TMS treatment system for depression.

The proof is in the efficacy data, which is what matters most to providers and patients. The NeuroStar system is cleared by the U.S. Food and Drug Administration (FDA) for multiple indications, including Major Depressive Disorder (MDD) in adults and adolescents. In the first half of 2025, the company saw a 25% growth in adolescent new patient starts, thanks in part to expanded insurance coverage. What this estimate hides, though, is the clinical validation that drove that coverage: real-world data from the TrakStar database showed that 78% of adolescent patients with MDD achieved a clinical response.

The full-year 2025 gross margin is expected to be between 48% and 50%, which reflects the inclusion of the Greenbrook clinic business. While this margin is lower than their historical product-only margin, it shows the investment in a vertically integrated model to control the quality of the patient experience from device to treatment session.

Pillar 3: Expanding Access and Compassion

The final component is the holistic approach that values compassion and integrity, which means making effective treatment accessible to more people. The acquisition of Greenbrook TMS Inc. was a major move here, transforming Neuronetics into a vertically integrated company that both sells the device and operates treatment centers.

This strategy is about removing barriers. The Greenbrook clinic revenue was $21.8 million in the third quarter of 2025, representing a 25% growth on an adjusted pro forma basis compared to the prior year. That growth isn't just a number; it represents thousands of patients gaining access to care. The company also continues to drive major insurance coverage expansions, with Evernorth Health Services (Cigna) joining others in covering adolescent TMS treatment.

It's a simple idea: mental health is as important as physical health. By integrating the clinical and technology sides of the business, Neuronetics is defintely making it easier for patients to get the help they need, whenever and wherever they need it.

Neuronetics, Inc. (STIM) Vision Statement

You're looking at Neuronetics, Inc. (STIM) because the neurohealth space is defintely a high-growth area, but you need to know if their stated purpose maps to their financial reality. The direct takeaway is that their vision, Neurohealth achieved for people everywhere, is a clear, actionable mandate that has driven a significant shift in their business model, evidenced by the massive revenue jump in 2025 following the Greenbrook TMS Inc. acquisition.

For a company operating in a specialized medical technology field like Transcranial Magnetic Stimulation (TMS), a visionary statement can't just be a poster on the wall; it has to be the driver of capital allocation and market strategy. Neuronetics' vision is the north star for the expansion of their NeuroStar Advanced Therapy system, pushing them beyond just selling devices into becoming a vertically integrated healthcare provider.

For a deeper dive into the company's foundation, see Neuronetics, Inc. (STIM): History, Ownership, Mission, How It Works & Makes Money.

The Vision: Neurohealth Achieved

The first part of the vision-Neurohealth achieved-is a commitment to clinical efficacy and patient outcomes. It's about delivering a result, not just a procedure. Their core product, NeuroStar, is a non-drug, noninvasive treatment for Major Depressive Disorder (MDD) and other neurohealth conditions, and this focus is what separates them from the pharmaceutical heavyweights.

The proof is in the scale: as of late 2025, NeuroStar has facilitated over 8.2 million treatment sessions globally, backed by the world's largest depression outcomes registry. This is not a small pilot program; it's a massive, real-world data set that underpins their Patient-Centricity core value. The financial performance reflects this commitment to delivery. Their total revenue for the first nine months of the 2025 fiscal year (Q1-Q3) reached approximately $107.4 million, showing that the market is validating their treatment-first approach. One clean line: The efficacy of the treatment is the ultimate growth driver.

The Mission: Renewing Lives by Transforming Neurohealth

The mission statement-Renewing lives by transforming neurohealth-explains how they achieve the vision. This transformation is happening through a dual strategy: technology sales and clinic operations. The acquisition of Greenbrook TMS Inc. is a concrete example of this mission in action, allowing them to control the patient experience and capture more of the value chain.

Here's the quick math on that integration: In Q3 2025, the U.S. clinic revenue, primarily from the Greenbrook acquisition, was $21.8 million, which is a 25% growth on an adjusted pro forma basis compared to Q3 2024. This clinic revenue now represents a substantial portion of their Q3 2025 total revenue of $37.3 million. What this estimate hides is the lower gross margin of 45.9% (down from 75.6% in Q3 2024) due to integrating the clinic business, but that's a trade-off for better market control and patient access, aligning with their Optimization core value.

• Sell the technology: Focus on system sales and recurring treatment session revenue.
• Control the experience: Manage the Greenbrook clinics to ensure quality and access.
• Expand access: Push for broader insurance coverage, like the New York State Medicaid expansion for TMS in October 2025.

The Scope: For People Everywhere

The phrase for people everywhere speaks directly to scalability, market access, and the core value of Community. Neuronetics is actively working to break down the geographic and financial barriers to Transcranial Magnetic Stimulation (TMS) therapy. The expansion of insurance coverage is crucial here; for example, the recent New York State Medicaid coverage for TMS for adults with MDD expands access to over 5 million members statewide. This is a massive tailwind.

Also, the company is not just focused on adults. The FDA clearance for adolescents aged 15 to 21 with MDD positions them for long-term growth, addressing a patient population of an estimated 4.3 million U.S. adolescents affected by major depression. This strategic push into new demographics and payor markets is the clearest sign that they are serious about the everywhere part of their vision.

Core Values as an Operating Framework

The remaining core values-Humility and Integrity-serve as the operational guardrails for this aggressive growth. Humility means acknowledging that the job is never done, pushing for continuous improvement, and valuing the perspectives of the physicians and patients who use the NeuroStar system. Integrity is about upholding high standards in all their work, especially when dealing with sensitive patient data and complex reimbursement models. The fact that they ended Q3 2025 with a strengthened balance sheet, holding $34.5 million in total cash, shows a commitment to financial integrity and responsible cash management, even as they pursue a growth-by-acquisition strategy.

Neuronetics, Inc. (STIM) Core Values

You're looking at Neuronetics, Inc. (STIM) because you see the potential in a company that's transforming mental health treatment, but a strong balance sheet is only half the story. The core values-the operating philosophy-tell you how they plan to sustain that growth. For a medical technology firm, these values aren't just posters on a wall; they dictate everything from R&D spend to patient access strategy.

The company's mission is clear: renewing lives by transforming neurohealth. Their vision is equally ambitious: neurohealth achieved for people everywhere. To be fair, a lot of companies have a great mission. But Neuronetics backs it up with a focus on a few key values that are directly tied to their operational and financial performance, especially as they project a full-year 2025 revenue between $147 million and $150 million.

Patient-Centricity & Compassion

This value is the bedrock of a successful medical device company. Compassion means prioritizing patient well-being and access, not just system sales. For Neuronetics, this translates into a relentless focus on expanding the reach of their NeuroStar Advanced Therapy System, a non-invasive treatment for Major Depressive Disorder (MDD).

Their commitment is defintely visible in their operational moves. For example, the acquisition of Greenbrook TMS Inc. in late 2024 was a massive step, instantly creating a vertically integrated company with over 95 treatment clinics across the U.S. This move wasn't just about revenue-it was about controlling the patient experience and improving access to care. Plus, as of Q3 2025, they've already treated over 229,429 global patients with 8.2 million treatment sessions. That's a huge volume of real-world data driving their next moves.

• Expanded New York State Medicaid coverage for NeuroStar in late 2025, opening access to over 5 million members.
• The focus is on delivering exceptional, non-drug treatment options.

Optimization & Operational Excellence

As a financial analyst, I look at optimization as the bridge between a great product and a profitable business. It's about efficiency, effectiveness, and innovation. After the Greenbrook acquisition, the immediate focus was on integrating the operations to drive better results for both patients and shareholders. That's just smart business.

Here's the quick math: Neuronetics identified over $22 million in annual cost synergies from the Greenbrook deal, with over 90% of those synergies already implemented early in 2025. That's a clear action mapping to the value of optimization. They also rolled out the Best Practice Model (BMP) program for their clinics, which showed concrete results by reducing the time from patient interest to motor threshold determination by 2.5x at participating sites. That's operational excellence in action.

• Q3 2025 Greenbrook clinic revenue was $21.8 million, a 25% growth on an adjusted pro forma basis versus Q3 2024, showing the synergy is working.
• They are targeting positive cash flow from operations in the fourth quarter of 2025.

If you want to dig deeper into the numbers behind these operational shifts, you should check out Breaking Down Neuronetics, Inc. (STIM) Financial Health: Key Insights for Investors.

Integrity & Humility

In the medical technology space, integrity is non-negotiable; it means ethical behavior, transparency, and a commitment to data. Humility means acknowledging that you don't have all the answers and that continuous growth is necessary. Neuronetics demonstrates this by grounding their work in the largest clinical data set of any Transcranial Magnetic Stimulation (TMS) system for depression.

Their transparency, even when the news isn't perfect, is a sign of integrity. For instance, in their Q3 2025 earnings release, they openly reported a net loss of $(0.13) per share, missing the analyst estimate of $(0.10). They also disclosed the decline in gross margin to 45.9% from 75.6% in Q3 2024, explaining it was primarily due to the inclusion of the lower-margin Greenbrook clinic business. This kind of clear, unvarnished reporting builds trust with the market and shows they prioritize accurate communication over spin.

• They maintain the world's largest depression Outcomes Registry for their NeuroStar therapy.
• The company's full-year 2025 operating expenses are projected to be between $100 million and $105 million, a clear, forward-looking financial commitment.